Show source-provided references
6. Breijyeh, Z., and Karaman, R. (2020). Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules, 25.
10.3390/molecules25245789 ↗8. Mini-Mental State Examination (MMSE) for the detection of Alzheimer’s disease and other dementias in people with mild cognitive impairment (MCI)
10. Spreading of Amyloid, Tau, and Microvascular Pathology in Alzheimer’s Disease: Findings from Neuropathological and Neuroimaging Studies
10.3233/JAD-141461 ↗12. Age-specific and Sex-specific Prevalence and Incidence of Mild Cognitive Impairment, Dementia, and Alzheimer Dementia in Blacks and Whites
10.1097/WAD.0b013e31823dbcfc ↗13. Intranasal Piperine-Loaded Chitosan Nanoparticles as Brain-Targeted Therapy in Alzheimer’s Disease: Optimization, Biological Efficacy, and Potential Toxicity
10.1002/jps.24557 ↗14. Larsson, S., and Orsini, N. (2018). Coffee Consumption and Risk of Dementia and Alzheimer’s Disease: A Dose-Response Meta-Analysis of Prospective Studies. Nutrients, 10.
10.3390/nu10101501 ↗15. Prince, M., Albanese, E., Guerchet, M., and Prina, M. (2014). World Alzheimer Report 2014 Dementia and Risk Reduction, Alzheimer’s Disease International.
18. Prince, M., Wimo, A., Guerchet, M., Ali, G., Wu, Y., and Prina, M. (2015). World Alzheimer Report 2015—The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends, Alzheimer’s Disease International.
20. Gender and Age Differences and the Trend in the Incidence and Prevalence of Dementia and Alzheimer’s Disease in Taiwan: A 7-Year National Population-Based Study
10.1155/2019/5378540 ↗22. The Prevalence and Incidence of Dementia Due to Alzheimer’s Disease: A Systematic Review and Meta-Analysis
10.1017/cjn.2016.36 ↗23. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group
27. Characterization of Dementia and Alzheimer’s Disease in an Older Population: Updated Incidence and Life Expectancy with and without Dementia
10.2105/AJPH.2014.301935 ↗28. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019
10.1016/S2468-2667(21)00249-8 ↗29. (2021). 2021 Alzheimer’s disease facts and figures. Alzheimer’s Dement., 17, 327–406.
10.1002/alz.12328 ↗30. Trends in the incidence and prevalence of Alzheimer’s disease, dementia, and cognitive impairment in the United States
10.1016/j.jalz.2010.11.002 ↗32. The existence of primary age-related tauopathy suggests that not all the cases with early braak stages of neurofibrillary pathology are Alzheimer’s disease
10.3233/JAD-150435 ↗33. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease
10.1073/pnas.90.5.1977 ↗34. Katzman, R., and Kawas, C. (1994). The epidemiology of dementia and Alzheimer disease. Alzheimer Disease, UC Irvine.
35. Neurodegeneration in Alzheimer Disease: Role of Amyloid Precursor Protein and Presenilin 1 Intracellular Signaling
10.1155/2012/187297 ↗39. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: A systematic review and meta-analysis
10.1016/S1474-4422(09)70236-4 ↗43. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: The HAAS☆
45. Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer’s disease
10.1172/JCI6179 ↗48. Glycogen Synthase Kinase 3 Inhibitors in the Next Horizon for Alzheimer’s Disease Treatment
10.4061/2011/280502 ↗50. Amyloid-β Peptides and Tau Protein as Biomarkers in Cerebrospinal and Interstitial Fluid Following Traumatic Brain Injury: A Review of Experimental and Clinical Studies
10.3389/fneur.2013.00079 ↗53. Alzheimer Disease and Oxidative Stress
56. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer‘s disease
10.1093/brain/awu213 ↗60. Regional Distribution of Neuritic Plaques in the Nondemented Elderly and Subjects with Very Mild Alzheimer Disease
10.1001/archneur.55.9.1185 ↗61. Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein
10.1126/science.1255555 ↗64. Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: Cause or effect?
10.1172/JCI22317 ↗65. Neurofibrillary Tangles Mediate the Association of Amyloid Load with Clinical Alzheimer Disease and Level of Cognitive Function
10.1001/archneur.61.3.378 ↗70. Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients with Mild Cognitive Impairment or Dementia Due to Alzheimer Disease
10.1001/archneurol.2011.150 ↗72. Tacrine therapy for the dementia of Alzheimer’s disease
73. Versatile Fluorescent Carbon Dots from Citric Acid and Cysteine with Antimicrobial, Anti-biofilm, Antioxidant, and AChE Enzyme Inhibition Capabilities
10.1007/s10895-021-02798-x ↗76. Birks, J.S. (2006). Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database of Systematic Reviews, John Wiley & Sons, Ltd.
10.1002/14651858.CD005593 ↗79. Suner, S.S., Sahiner, M., Ayyala, R.S., Bhethanabotla, V.R., and Sahiner, N. (2020). Nitrogen-Doped Arginine Carbon Dots and Its Metal Nanoparticle Composites as Antibacterial Agent. C—J. Carbon Res., 6.
10.3390/c6030058 ↗80. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease
10.1111/ene.12707 ↗81. Memantine in patients with Alzheimer’s disease receiving donepezil: New analyses of efficacy and safety for combination therapy
10.1186/alzrt160 ↗83. Antidepressants for treating depression in dementia
85. Simvastatin strongly reduces levels of Alzheimer’s disease -amyloid peptides A 42 and A 40 in vitro and in vivo
10.1073/pnas.081620098 ↗87. Dietary Intake of Antioxidant Nutrients and the Risk of Incident Alzheimer Disease in a Biracial Community Study
10.1001/jama.287.24.3230 ↗88. Folic Acid Deficiency and Homocysteine Impair DNA Repair in Hippocampal Neurons and Sensitize Them to Amyloid Toxicity in Experimental Models of Alzheimer’s Disease
10.1523/JNEUROSCI.22-05-01752.2002 ↗89. Use of Magnetization Transfer Contrast MRI to Detect Early Molecular Pathology in Alzheimer’s Disease
10.1002/mrm.24665 ↗90. Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: Evidence from randomized, controlled clinical trials
10.1007/s10354-015-0360-y ↗91. Design, synthesis and evaluation of a novel metal chelator as multifunctional agents for the treatment of Alzheimer’s disease
10.1016/j.bioorg.2019.03.064 ↗93. Rosmarinic acid suppresses Alzheimer’s disease development by reducing amyloid β aggregation by increasing monoamine secretion
10.1038/s41598-019-45168-1 ↗94. Enhancement of biocompatibility and carbohydrate absorption control potential of rosmarinic acid through crosslinking into microparticles
10.1016/j.ijbiomac.2019.07.032 ↗95. Phytochemical profiling of Blumea laciniata (Roxb.) DC. and its phytopharmaceutical potential against diabetic, obesity, and Alzheimer’s
10.1016/j.biopha.2021.111859 ↗97. Sahiner, N. (2021). Self-Crosslinked Ellipsoidal Poly(Tannic Acid) Particles for Bio-Medical Applications. Molecules, 26.
10.3390/molecules26092429 ↗99. Benchikha, N., Messaoudi, M., Larkem, I., Ouakouak, H., Rebiai, A., Boubekeur, S., Ferhat, M.A., Benarfa, A., Begaa, S., and Benmohamed, M. (2022). Evaluation of Possible Antioxidant, Anti-Hyperglycaemic, Anti-Alzheimer and Anti-Inflammatory Effects of Teucrium polium Aerial Parts (Lamiaceae). Life, 12.
10.3390/life12101579 ↗100. Messaoudi, M., Rebiai, A., Sawicka, B., Atanassova, M., Ouakouak, H., Larkem, I., Egbuna, C., Awuchi, C.G., Boubekeur, S., and Ferhat, M.A. (2021). Effect of Extraction Methods on Polyphenols, Flavonoids, Mineral Elements, and Biological Activities of Essential Oil and Extracts of Mentha pulegium L.. Molecules, 27.
10.3390/molecules27010011 ↗